Genzyme Corporation

Sanofi

Sunghae Park

Huawei Qiu

Ronnie Rong Wei

Cendrine Lemoine

Clark Qun Pan

James E Stefano

Magali Mathieu

Marie Mandron

Jonathan Rothblatt

Aaron Moulin

Kara Carter

William Harold Brondyk

Qun Zhou

Marie-Priscille Brun

Yangde Chen

Francis Duffieux

Yu Qiu

Yanfeng Zhou

HyunSuk Cho

Yves Sabbagh

Ronnie Wei

The present invention concerns antibodies and antigen-binding fragments of antibodies which specifically bind to and neutralize Chikungunya virus (CHIKV) and which are engineered to develop therapeutics in order to treat CHIKV disease or prevent CHIKV infection. The invention also relates to pharmaceutical compositions comprising antibodies of the invention and the use of the antibodies for the prevention and treatment of CHIKV disease.

Anti-CHIKV antibodies and uses thereof

Provided are recombinant and chemically-conjugated antibodies and fragments thereof modified with one or more poly-aspartate (poly-D) peptides (e.g., a D10 sequence) to improve localization of the antibodies or fragments to bone. Methods of making and using of these antibodies and fragments also are disclosed.

Bone-targeting antibodies

Engineered antibodies that are stable and can be conjugated to a ligand or drug at a ligand/drug to antibody ratio of above 3, making these conjugates suitable for treatment of a variety of indications, are provided. Methods of producing these engineered antibodies are also provided.

Modified binding polypeptides for optimized drug conjugation

Anti-FGFR3 antigen-binding proteins and antigen-binding binding fragments thereof are provided. Methods of inhibiting FGFR3 activity and methods of treating FGFR3-mediated diseases and disorders are also provided.

FGFR3 antibodies and methods of use

Anti-CHIKV monoclonal antibodies directed against the E2 structural protein

Antibodies or antigen-binding fragments thereof are engineered to bind Transforming Growth Factor-&#x3b2; (TGF&#x3b2;). TGF&#x3b2;-isoform selective antibodies or antigen-binding fragments thereof may selectively bind human TGF&#x3b2;1, compared to human TGF&#x3b2;2 and human TGF&#x3b2;3, or may selectively bind human TGF&#x3b2;3, compared to human TGF&#x3b2;1 and human TGF&#x3b2;2. The design of the antibodies or antigen-binding fragments thereof is facilitated by a co-crystal structure of a recombinant Fab fragment of GC1008 bound to TGF&#x3b2;2 and by another co-crystal structure of the scFv version of GC1008 bound to TGF&#x3b2;1.

Engineered anti-TGF-&#x3b2; antibodies and antigen-binding fragments

Engineered anti-TGF-beta antibodies and antigen-binding fragments

Growing community of inventors

Bridgewater, NJ, United States of America

Sunghae Park